This study suggests that there is a strong indication for LMCT for HCCs measuring 40 mm or less in diameter and those located on the liver surface even if they are as large as 50 mm, but not for those located close to the gallbladder or in contact with the diaphragm. LMCT appears to be applicable in patients with impaired liver function.

Myoepithelial carcinoma of the breast is extremely rare and only 33 cases have been reported in the English literature. Herein, we report a case of myoepithelial carcinoma of the breast with focal rhabdoid features. The patient was a 67-year-old woman, who presented with a lump of the left breast that rapidly grew to 3 cm in diameter within 3 months. Lumpectomy revealed a solid and whitish colored tumor, which was composed mainly of elongated spindle-shaped cells with mild atypia, focal necrosis, and infiltrative margin. In a small area of the lesion, ovoid tumor cells exhibited eccentric nuclei with centrally located nucleoli and plump cytoplasm including round eosinophilic inclusions, resembling a rhabdoid tumor. Immunohistochemically, both types of tumor cells exhibited a myoepithelial phenotype. MIB-1 index was 30%. The cytoplasmic inclusion of the ovoid cells exhibited immunopositivity for both vimentin and cytokeratin. From these findings, this tumor was diagnosed as a myoepithelial carcinoma with focal rhabdoid features. Although rhabdoid features have been reported in some types of malignant and benign tumors, this is the first report of such features in myoepithelial carcinoma of the breast.

No abstract

No abstract

and to investigate its activity in combination with cytotoxic drugs. 5 We demonstrated that the selected case of c-KIT overexpression in squamous cell carcinoma of the uterine cervix from our previous preliminary report also showed significant PDGFRA protein overexpression, but no PDGFRA gene activating mutations. Although the tissue materials used in both the aforementioned studies (Taja-Chayeb 6 and Longatto-Filho 7 ) were not restricted to the squamous cell type, our findings are in agreement with the described absence of activating mutations in cervical carcinogenesis.By correlating the immunophenotype with the molecular status of the genes expected to be involved, our findings suggest that c-KIT ⁄ PDGFRA immunophenotyping is not useful in predicting the presence of c-KIT and PDGFRA mutations in squamous cell carcinoma of the uterine cervix. Although the absence of c-KIT and PDGFRA mutations may support limiting the use of imatinib (Gleevec) and sunitinib (Sutent) targeting receptor tyrosine kinases (RTKs) to such clinical trials as therapeutic options for squamous cell carcinoma of the uterine cervix, current molecular profiling of the coexpression of KIT and PDGFRA with wild-type c-KIT and PDGFRA oncogenes will still be valuable in selecting other newly developed specific anti-RTK drugs.